Warsaw-based biotech startup Ingenix.ai, a co-pilot for clinical development, has secured €9 million in funding for simulating clinical trials with AI. Investors include Inovo, OTB Ventures, and IFC.
- Launched in 2023 by Piotr Surma and Adam Dancewicz, Ingenix.ai develops a foundation model for simulating clinical trials using digital twins.
- The model is trained on multimodal biological data, including genomic, transcriptomic, proteomic, imaging, and phenotypic inputs, and simulates biological processes across multiple scales, from molecular interactions to population-level outcomes.
- The system performs low-level predictions such as molecular docking and pathway activation, which inform higher-level clinical results.
- Researchers can interact with the model via natural language to examine predicted clinical endpoints, adverse events, and drug interactions.
Details of the deal
- The recent funding round was led by Inovo.vc, a Warsaw-based venture capital firm that supports early-stage startups across Poland and the Central and Eastern Europe (CEE) region, typically investing between €500,000 and €4 million.
- OTB Ventures, which launched a €150 million deeptech fund in 2024, and the International Finance Corporation (IFC), a member of the World Bank Group, also participated in the round.
- The fresh funds will enable Ingenix.ai to expand its AI and biology research team, advance its reasoning-based foundation model, integrate diverse multimodal datasets, and scale its infrastructure for large-scale clinical trial simulations using digital twins.
"With world-class researchers in both AI and biology - and access to rich datasets across multiple scales - we’re on the verge of building truly reasoning AI for clinical trials. We are excited to have Inovo, OTB Ventures, and IFC on board - partners who truly share our vision for the future of AI in clinical drug development," Ingenix.ai's team, commented on LinkedIn.
